#### **Session 3: The Future of GCP Inspections**

Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Symposium February 14, 2024 – 11:25 – 12:15 AM

Moderator: **Kassa Ayalew, MD, MPH** *Division Director* | DCCE | OSI | OC | CDER | FDA

Jenn Sellers, MD, PhD Branch Chief | GCPAB | DCCE | OSI | OC | CDER | FDA

#### Jennifer Adams, MPH

Lieutenant Commander (LCDR) | USPHS Foreign Cadre Director | OBIMO | OMPTO | ORA | FDA

#### **Rachel Mead, BSc**

Senior GCP Inspector | MHRA



#### **Remote Regulatory Assessment (RRA) for Marketing Application Review**

#### Jenn Sellers, M.D., Ph.D., FAAP

**Branch Chief GCP** Assessment Branch **Division of Clinical Compliance Evaluation** Office of Scientific Investigations Office of Compliance/CDER/FDA

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop February 13-15, 2024



Medicines & Healthcare products **Regulatory Agency** 



Santé Canada Canada

Health

#### **Disclaimer**

The views and opinions presented here represent those of the speaker and should not be considered to represent advice or guidance of the U.S. Food and Drug Administration.

#### **Overview**

• Experience of remote regulatory assessment (RRA) during the pandemic

Lessons learned from marketing application review

• Future use of RRAs

# **GCP Inspections for NDAs/BLAs**

- Clinical Investigator (CI)
- Sponsor-investigator
- Sponsor
- Contract Research Organization (CRO)

#### **Compliance Review Process for NDAs/BLAs**

Review Divisions receive NDAs/BLAs with clinical trial data Make decision on GCP inspections using a risk-based approach


Inspection assignment memo issued to inspectors

Review Divisions make marketing approval decisions Inspection results reviewed and inspection summary reported to Review Divisions



Inspection conducted and results reported

6



#### **Remote Regulatory Assessment (RRA)**

 Remote examination of an FDA-regulated establishment and/or its records to evaluate compliance with applicable FDA requirements

#### Similarities and Differences Between GCP Inspection and RRA

#### RRA

- Remote
- No credentials
- No FDA 482
- No FDA 483, but can provide observations in writing

- Meetings with establishment
- Verify documents/data
- Evaluate compliance
- Observations in writing
- Regulatory actions can be taken if objectionable observations exist

#### Inspection

- FDA official physically enters an establishment
- Display credentials
- Issue FDA 482
- Can issue FDA 483

# **RRAs During Pandemic FY20-21**

#### FY20


- 39 RRAs
- Oncology and anti-viral


#### FY21

- 33 RRAs
- Oncology and rare diseases

#### Total Number = 72

#### RRAs in FY20-21





#### **Lesson Learned**

- RRAs were useful in the assessment of data reliability, subject safety, and clinical trial conduct
- RRAs supported FDA's mission and informed the agency the regulatory decisions for the marketing applications during the pandemic

# **Benefits of an RRA**

- Valuable tool to verify data submitted
- Allow FDA to assess GCP and regulatory compliance remotely to support regulatory decisions
- Expand the breadth of FDA's GCP oversight
- Potential to save resources (travel time, money)

# When May FDA Request an RRA?

 When FDA determines that an RRA will assist in the oversight of establishments or support regulatory decisions

• When FDA cannot conduct an inspection due to travel limitations

# **Take-home Message**

# RRA is a valuable tool for regulatory authorities to assess GCP compliance

## Acknowledgement

- Kassa Ayalew, M.D., MPH
- Phillip D. Kronstein, M.D.
- Laurie Muldowney, M.D.
- Emily Gebbia, J.D.
- Jean Mulinde, M.D.
- David Burrow, Pharm.D., J.D.
- Yolanda Patague
- Amir Tahami, M.B.A.
- Staff in the Office of Scientific Investigations
- Staff in the Office of Regulatory Affairs

#### Resources

- <u>Conducting Remote Regulatory Assessments</u> <u>Questions and Answers. Draft Guidance for Industry.</u> <u>JANUARY 2024</u>
- ORIGINAL RESEARCH

The United States Food Drug Administration's Innovative Alternative Tools to Evaluate Good Clinical Practice During the COVID-19 Public Health Emergency

Kassa Ayalew, Jenn W. Sellers, Phillip D. Kronstein, Laurie Muldowney, Emily Gebbia, Jean Mulinde and David Burrow



#### The Future of GCP Inspections

#### **Jennifer Adams**

Lieutenant Commander, US Public Health Service Foreign Cadre Director Office of Bioresearch Monitoring | U.S. Food and Drug Administration

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop February 13-15, 2024



Medicines & Healthcare products **Regulatory Agency** 




Santé Canada Canada

Health


#### **Topics**

- Evolution of the Remote Regulatory Assessment (RRA)
- RRAs in the transition and steady state
- Looking towards our future

### **Evolution of the RRA - Foreign**




### **Evolution of the RRA – Domestic**




## **Pandemic RRAs - Analysis**

- Resource Burn
- Coverage

#### **Resource Burn**





### **RRAs in the steady state - 2023**



# Looking towards our future

3

4

5

6

Contains Nonbinding Recommendations Draft — Not for Implementation

# Conducting Remote Regulatory Assessments

Questions and Answers Draft Guidance for Industry

This draft guidance document is for comment purposes only.



## **The Future of GCP Inspections**

#### **Rachel Mead**

Senior GCP Inspector Compliance Team 1 Medicines and Healthcare products Regulatory Agency

A Joint US-FDA | MHRA-UK | Health Canada Good Clinical Practice & Pharmacovigilance Compliance Workshop February 13, 2024



Medicines & Healthcare products Regulatory Agency



Health Canada

Santé Canada

# **UK inspections**

#### SI 2004/1031 and SI 2006/1928

- Right to inspect any site involved in clinical trial activities in the UK
- Fees to be charged for inspections associated with clinical trials

#### HMR 2012/1916 Regulations 325, 327 and 328


Covers rights of entry, powers of inspection and sampling and seizure

# **Types of MHRA GCP inspections**

- National Programme
  - Risk-based: systems or study-specific
  - Triggered: systems or study-specific
  - Voluntary Phase 1 Accreditation Scheme
- Requested Inspections, MAA related
  - Requested by MHRA Assessors
- > Joint inspections with other agencies

# Types of organisations inspected

- Commercial and non-commercial sponsors
- Investigator sites
- Contract Research Organisations (CROs)
- Specialist providers (e.g. eSystem Vendors)
- > Laboratories
- Non-commercial Clinical Trial Units
- Phase 1 units
- > Bioequivalence/Biosimilar facilities



# What did the pandemic change?

Move to a remote only programme

- Review TMF remotely
- Focus on trial oversight and effective change control procedures
- eSystem focus on data integrity and controls

# **GCP challenges for trials**

- Recruitment pauses and temporary halts
- Missing data
- Scientific advice on usability of data
- Protocol deviations
- Re-monitoring required?
- Participants receiving vaccines, vaccine trials unblinding

# **GCP** remote inspection outcomes Consent of trial participants > Reliability of the trial endpoints $\geq$ QC activities in relation to data management > Monitoring for data integrity

# The future of remote inspections?

- A hybrid approach to GCP inspections will continue to be used
- > A positive response from industry
- Also a benefit to the public

# The future of GCP inspections?

- Work has commenced on drafting proposed changes to UK legislation based on public consultation (2138 responses received)
- New International Recognition Procedure
  Upcoming programme of MAA inspections

# **Copyright information**

#### © Crown copyright 2024

Produced by the Medicines and Healthcare products Regulatory Agency

You may re-use this information (excluding logos) with the permission from the Medicines and Healthcare products Regulatory Agency, under a Delegation of Authority. To view the guideline, visit <u>https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information</u> or email: <u>copyright@mhra.gov.uk</u>.

Where we have identified any third-party copyright material you will need to obtain permission from the copyright holders concerned.

The names, images and logos identifying the Medicines and Healthcare products Regulatory Agency are proprietary marks. All the Agency's logos are registered Trademarks and cannot be used without the Agency's explicit permission.

# **Questions?**

#### **Rachel Mead**

Senior GCP Inspector Compliance Team 1 Medicines and Healthcare products Regulatory Agency

clintrialhelpline@mhra.gov.uk

#### Summary

- GCP RRAs are a valuable tool for regulatory authorities to assess compliance, but will not replace GCP inspections due to their limitations.
- Preparation for onsite and remote inspections is similar. Document review, interviews and document requests don't change just because an inspector is in their home office rather than a conference room in your head office.